Physician profile
Paul E Mcmanus
NPI 1053312959
$2,501.33
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $382 · 2021: $543 · 2022: $457 · 2023: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $525.62 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $278.70 | 2019-2023 | Cequa |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Alcon Vision LLC | $187.35 | 2020-2023 | Rocklatan, Simbrinza |
| Abbvie INC. | $159.50 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $159.43 | 2019-2023 | Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $159.41 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $137.61 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $111.86 | 2022-2023 | Acthar |
| Glaukos Corporation | $78.65 | 2019-2023 | |
| Iridex Corporation | $74.71 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $64.26 | 2019-2022 | |
| Rxsight INC | $53.88 | 2022-2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Light Adjustable Lens (Rxlal) |
| Oyster Point Pharma, INC. | $52.76 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $29.93 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $24.08 | 2023 | Iyuzeh |
| Akorn, INC. | $23.06 | 2020 | |
| Akorn Operating Company LLC | $20.99 | 2021 | |
| Shire North American Group INC | $17.37 | 2019 | |
| Ocular Therapeutix, INC. | $17.22 | 2019 | |
| Horizon Therapeutics Plc | $15.59 | 2023 | Tepezza |
| Genentech USA, INC. | $15.21 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.93 | 2021 | |
| Omeros Corporation | $14.87 | 2021 | |
| Bausch & Lomb Americas INC. | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.